Literature DB >> 10385545

Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival.

F Parazzini1, G Valsecchi, G Bolis, P Guarnerio, S Reina, G Polverino, D Silvestri.   

Abstract

BACKGROUND: In order to analyze the prognostic role of node involvement in advanced ovarian cancer, we have analyzed data from a randomized clinical trial on advanced ovarian cancer.
METHODS: Cases were 456 women who entered a randomized multicentric clinical trial comparing two cisplatin-based schemes of treatment after cytoreductive surgery for advanced stage III-IV ovarian cancer. They underwent selective pelvic and/or paraortic lymphadenectomy.
RESULTS: A total of 161 (35.3%) cases had positive nodes. The frequency of positive nodes was statistically significantly higher in FIGO stage IV than in stage III. Also grade 3 tumors were more likely to have positive nodes than grade 1-2 tumors. No association was observed between nodal status and response to chemotherapy. The 3-year survival was 46.2 (standard error (SE) = 3.4 based on 147 deaths) and 44.6 (SE = 4.4, based on 84 deaths), respectively, in negative and positive node groups. The corresponding values, when the analysis was performed considering only subjects with residual tumor <1 cm or absent, after first-line cytoreductive surgery were 66.2 (SE = 5.7) and 62.4 (SE = 9.6).
CONCLUSIONS: We did not find any association between nodal status and survival. Particularly, nodal status was not a prognostic factor for survival in the subgroup of women with residual tumor <1 cm or absent after cytoreductive surgery. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10385545     DOI: 10.1006/gyno.1999.5397

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Perimenopausal ovarian carcinoma patient with subclavian node metastasis proven by immunohistochemistry.

Authors:  Hee Jeong Jeong; Hyun Joo Kim; Eun Hee Lee; Hyoun Wook Lee; Min Kyu Kim
Journal:  J Menopausal Med       Date:  2014-04-28

3.  Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report.

Authors:  Shigao Huang; Yazheng Dang; Fujun Li; Wei Wei; Yuxin Ma; Song Qiao; Qianyun Wang
Journal:  Oncol Lett       Date:  2014-12-22       Impact factor: 2.967

4.  The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials.

Authors:  Qingqing Lin; Wenchao Liu; Song Xu; Juan Li; Jinyi Tong
Journal:  J Ovarian Res       Date:  2020-05-08       Impact factor: 4.234

5.  Role of primary surgery in advanced ovarian cancer.

Authors:  Karsten Münstedt; Folker E Franke
Journal:  World J Surg Oncol       Date:  2004-10-02       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.